Edgar Filing: ANIKA THERAPEUTICS INC - Form 3

ANIKA THERAPEUTICS INC

Form 3

January 08, 2010

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement ANIKA THERAPEUTICS INC [ANIK] Fidia Farmaceutici S.p.A. (Month/Day/Year) 12/30/2009 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) VIA PONTE DELLA (Check all applicable) FABBRICA 3/A (Street) 6. Individual or Joint/Group _X_ 10% Owner Director Officer Other Filing(Check Applicable Line) (give title below) (specify below) Form filed by One Reporting Person **ABANO TERME** _X_ Form filed by More than One (PD), L6Â CAP 35031 Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 1. Title of Security 2. Amount of Securities 4. Nature of Indirect Beneficial Beneficially Owned Ownership Ownership (Instr. 4) (Instr. 4) Form: (Instr. 5) Direct (D) or Indirect (I) (Instr. 5) $D_{\underline{}}^{(1)}$ Â Common Stock 1,981,192 Common Stock 1,981,192 $I^{(1)}$ See Footnote (1) Reminder: Report on a separate line for each class of securities beneficially SEC 1473 (7-02) owned directly or indirectly. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

currently valid OMB control number.

. Title of Derivative Security Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	Securities Underlying	4. Conversion or Exercise	5. Ownership Form of	6. Nature of Indirect Beneficial Ownership (Instr. 5)
		(Instr. 4)	Price of	Derivative	

Edgar Filing: ANIKA THERAPEUTICS INC - Form 3

Date Expiration Title Amount or Derivative Security:

Exercisable Date Number of Security Direct (D)

Shares or Indirect

(I)

(Instr. 5)

Reporting Owners

Reporting Owner Name / Address		Relationships			
		10% Owner	Officer	Other	
Fidia Farmaceutici S.p.A. VIA PONTE DELLA FABBRICA 3/A ABANO TERME (PD), L6 CAP 35031	Â	ÂX	Â	Â	
P&R S.p.A. VIA MILANO N. 186 GARBAGNATE MILANESE (MI), L6 CAP 20024	Â	ÂX	Â	Â	
Fiore Holding S.r.l. VIA PRINCIPE AMEDEO N. 3 MILANO (MI), L6 CAP 20121	Â	ÂX	Â	Â	

Signatures

/s/ Antonio Germani, as Chief Executive Officer for Fidia Farmaceutici S.p.A. 01/08/2010

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- 1,981,192 shares of Common Stock, \$0.01 par value of the Issuer are beneficially owned directly by Fidia Farmaceutici S.p.A. ("Fidia") and may be deemed to be beneficially owned indirectly by (i) P&R S.p.A. ("P&R"), which controls and directly owns a majority of the outstanding equity of Fidia and (ii) Fiore Holding S.r.l. ("Fiore"), which controls and directly owns a majority of the outstanding equity of P&R. Each of P&R and Fiore disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2